# US 2019/0241520 A1 · Cyclohexene compounds and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241520 A1
- Document ID: US20190241520A1
- Status: Published application
- Kind: A1
- Application number: 16/331,797
- Filed: 2017-09-05
- Published: 2019-08-08
- Earliest claimed: 2016-09-09
- Assignees: Guangzhou Henovcom Bioscience Co., Ltd.
- Applicants: Guangzhou Henovcom Bioscience Co. Ltd
- Inventors: Jiancun Zhang; Kun Wang; Yan Liu; Deyao Li
- Web page: https://patentgrep.com/patent/US20190241520A1

## CPC

- C07D 211/42: attached in position 3 or 5
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/16: for influenza or rhinoviruses
- C07D 211/22: by oxygen atoms
- C07D 211/32: by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A cyclohexene compound and use thereof, which relates to the technical field of pharmaceutical chemistry is provided. The cyclohexene compound is the cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester group prodrug or a stereoisomer thereof. It is verified by activity assay for influenza NA that the cyclohexene compound has a great inhibiting activity against both wild-typed and drug-resistant influenza viruses, and the inhibiting activity IC50 of some compounds against wild-typed and drug-resistant influenza viruses is lower than 5 nM, showing significant inhibiting effect on influenza viruses. This shows that the cyclohexene compound or a pharmaceutically acceptable salt or a stereoisomer thereof has superior application prospect on preparing anti-influenza drugs, thereby providing a new drug choice for treating influenza clinically.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A cyclohexene compound having a structural formula I or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof:
wherein,
R is selected from H, an ion of M, or C1˜C6 alkyl;
M is selected from Na+, Ca2+, Mg2+, K+, Li+, or (HNR6R7R8)+;
R6, R7, and R8 are independently selected from H, C1˜C4 alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, substituted C3˜C6 cycloalkyl, C3˜C6 heterocyclyl, or substituted C3˜C6 heterocyclyl;
R1 is selected from amino, amidino, or guanidyl;
R2 is selected from H, C1˜C4 alkyl, or C1˜C4 alkenyl;
m is selected from 0 or 1;
R3 and R4 are independently selected from H, C1˜C4 alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, substituted C3˜C6 cycloalkyl, C3˜C6 heterocyclyl, or substituted C3˜C6 heterocyclyl;
n is selected from 1, 2, 3, or 4;
X is absent, or X is selected from CH2, O, S, NHCOO, OCONR9R10, or NHSO2;
R5 is absent, or R5 is selected from H, C1˜C4 alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, substituted C3˜C6 cycloalkyl, C3˜C6 heterocyclyl, or substituted C3˜C6 heterocyclyl; and
R9 and R10 are independently selected from H, C1˜C4 alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, or substituted C3˜C6 cycloalkyl, or R9 and R10 together with the atom to which they are attached form a C3˜C6 heterocyclic ring containing O, S, NH.

### Claim 11 (depends on 10)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof and wherein, R, R1, R2, R3, R4, R5, X, m and n are according to claim 10, wherein the cyclohexene compound is a compound having formula II:

### Claim 12 (depends on 10)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof and wherein R, R1, R2, R3, R4, R5, R9, R10 and n are according to claim 10, wherein the cyclohexene compound is a compound having formula III:

### Claim 13 (depends on 11)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof according to claim 11, wherein,
R is selected from H;
R1 is selected from amino, or guanidyl;
R2 is selected from C1˜C4 alkyl;
R3 and R4 are independently selected from H;
n is selected from 2;
X is selected from O, NHCOO, NHCOO, or OCONR9R10;
R5 is absent, or R5 is selected from H, C1˜C4 alkyl, substituted C1˜C4, alkyl, C3˜C6 cycloalkyl, substituted C3˜C6 cycloalkyl, C3˜C6 heterocyclyl, or substituted C3˜C6 heterocyclyl; and
R9 and R10 are independently selected from H, C1˜C4, alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, or substituted C3˜C6 cycloalkyl, or R9 and R10 together with the atom to which they are attached form a C3˜C6 heterocyclic ring containing O, S, NH.

### Claim 14 (depends on 12)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof according to claim 12, wherein,
R is selected from H;
R1 is selected from amino, or guanidyl;
R2 is selected from C1˜C4 alkyl;
R3 and R4 are independently selected from H;
n is selected from 2;
X is selected from O, NHCOO, NHCOO, or OCONR9R10;
R5 is absent, or R5 is selected from H, C1˜C4 alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, substituted C3˜C6 cycloalkyl, C3˜C6 heterocyclyl, or substituted C3˜C6 heterocyclyl; and
R9 and R10 are independently selected from H, C1˜C4 alkyl, substituted C1˜C4 alkyl, C3˜C6 cycloalkyl, or substituted C3˜C6 cycloalkyl, or R9 and R10 together with the atom to which they are attached form a C3˜C6 heterocyclic ring containing O, S, NH.

### Claim 15 (depends on 10)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer and having R, R1, and R2 as defined according to claim 10, wherein the cyclohexene compound is a compound having formula IV:
wherein, X is selected from CH2 or O; and
R5 is selected from H, C1˜C4 alkyl, C3˜C6 cycloalkyl, substituted C3˜C6 cycloalkyl, C3˜C6 heterocyclyl, or substituted C3˜C6 heterocyclyl.

### Claim 16 (depends on 10)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof according to claim 10, wherein,
substituted C1˜C4 alkyl is selected from hydroxyethyl, methoxyethyl, or ethoxyethyl;
C3˜C6 cycloalkyl is selected from cyclopropyl substituted methyl; and
substituted C3˜C6 heterocyclyl is selected from 4-carbonyloxymorpholinyl.

### Claim 17 (depends on 10)

The cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof according to claim 10, wherein the cyclohexene compound is a compound selected from one of the following compounds:

### Claim 18 (depends on 10)

A method of preventing and treating influenza in a subject in need thereof, comprising administering the cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof according to claim 10 in the preparation of a medicament.

### Claim 19 (depends on 10)

A pharmaceutical composition, comprising the cyclohexene compound or a pharmaceutically acceptable salt, an ester prodrug or a stereoisomer thereof according to claim 10, and a pharmaceutically acceptable excipient or carrier.
